1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Birch Pollen Allergy - Pipeline Review, H1 2016

Birch Pollen Allergy - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 52 pages

Birch Pollen Allergy - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Birch Pollen Allergy - Pipeline Review, H1 2016’, provides an overview of the Birch Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Birch Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy
- The report reviews pipeline therapeutics for Birch Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Birch Pollen Allergy therapeutics and enlists all their major and minor projects
- The report assesses Birch Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Birch Pollen Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Birch Pollen Allergy - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Birch Pollen Allergy Overview 7
Therapeutics Development 8
Pipeline Products for Birch Pollen Allergy - Overview 8
Birch Pollen Allergy - Therapeutics under Development by Companies 9
Birch Pollen Allergy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Birch Pollen Allergy - Products under Development by Companies 13
Birch Pollen Allergy - Companies Involved in Therapeutics Development 14
ALK-Abello A/S 14
Allergopharma GmbH and Co. KG 15
Allergy Therapeutics Plc 16
Anergis SA 17
Biomay AG 18
Circassia Pharmaceuticals Plc 19
HAL Allergy BV 20
Stallergenes S.A. 21
Birch Pollen Allergy - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Allergen for Birch Allergy - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
AllerT - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
BM-31 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
PL-102 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Pollinex Quattro Tree - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
rBet v1-FV - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
STG-210 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Vaccine for Birch Pollen Allergy - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Birch Pollen Allergy - Recent Pipeline Updates 42
Birch Pollen Allergy - Dormant Projects 44
Birch Pollen Allergy - Discontinued Products 45
Birch Pollen Allergy - Product Development Milestones 46
Featured News and Press Releases 46
Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria 46
Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial 46
Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen 47
Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting 47
Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT 48
Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT 48
May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen 49
Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT 49
Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego 50
Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables
Number of Products under Development for Birch Pollen Allergy, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2016 14
Birch Pollen Allergy - Pipeline by Allergopharma GmbH and Co. KG, H1 2016 15
Birch Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H1 2016 16
Birch Pollen Allergy - Pipeline by Anergis SA, H1 2016 17
Birch Pollen Allergy - Pipeline by Biomay AG, H1 2016 18
Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 19
Birch Pollen Allergy - Pipeline by HAL Allergy BV, H1 2016 20
Birch Pollen Allergy - Pipeline by Stallergenes S.A., H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Birch Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2016 42
Birch Pollen Allergy - Dormant Projects, H1 2016 44
Birch Pollen Allergy - Discontinued Products, H1 2016 45

List of Figures
Number of Products under Development for Birch Pollen Allergy, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Routes of Administration, H1 2016 24
Number of Products by Stage and Routes of Administration, H1 2016 24
Number of Products by Molecule Types, H1 2016 26
Number of Products by Stage and Molecule Types, H1 2016 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.